Skip to main content

Advertisement

SpringerLink
Log in

Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

To investigate the relationship between chemotherapy dose intensity and therapy efficacy of different molecular subtypes. Clinical and pathological features of the patients with breast cancer were retreived from the hospital records. 315 patients were analyzed (251 showed clinical response, 38 acquired pCR). Patients with positive ER status, negative PR status, higher Ki67 level and higher RTDI had better therapy response. 13.5 and 84.5 % were identified the benchmark of Ki67 and RTDI, respectively. As the result of interior-subgroup comparison, luminal subgroups acquired better response rate when RTDI ≥ 84.5 %. In patients of luminal breast cancer, tumor size change arose from increasing of dose intensity and finally showed reached a plateau after RTDI ≥ 95 % (r 2 = 0.303, p < 0.001). As the result of intersubgroup comparison, TNBC patients were more likely to acquired better clinical and pathology response when RDTI < 84.5 %. Ki67 change arose sharply from increasing of dose intensity when RDTI < 84.5 % (r 2 = 0.656, p < 0.001), whereas the regression curve showed a terminal plateau in patients of RDTI ≥ 84.5 % (r 2 = 0.427, p < 0.001). Given lower RTDI, luminal patients are less likely to achieve response, and TNBC patients are associated with higher response rate. Dissimilar of therapy efficacy between luminal subtype and TNBC becomes inconspicuous as RTDI rises. Chemosensitivity may associate with dose intensity, especially in luminal subtypes, and tailored therapeutic strategies should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. Kaufmann M, von Minckwitz G, Bear HD et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927–1934

    Article  CAS  PubMed  Google Scholar 

  3. Kim Kwan Il, Lee Kyung Hee, Kim Tae Ryung et al (2014) Ki67 as a predictor of response to NAC in breast cancer patients. J Breast Cancer 17(1):40–46

    Article  PubMed Central  PubMed  Google Scholar 

  4. Kim SI, Sohn J, Koo JS et al (2010) Molecular subtypes and tumor response to NAC in patients with locally advanced breast cancer. Oncology 79:324–330

    Article  CAS  PubMed  Google Scholar 

  5. Sandy J, Della-Fiorentina S (2013) Relative dose intensity in early stage breast cancer chemotherapy: a retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic. J Clin Oncol 9(4):365–372

    Google Scholar 

  6. Loibl S, Skacel T, Nekljudova V et al (2011) Evaluation the impact of relative total dose intensity on patients` short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer-a pooled analysis. BMC Cancer 11:131

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving NAC for early breast cancer. Br J Cancer 91:2012–2017

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Yoo C, Ahn J-H, Jung KH et al (2012) Impact of immunohistochemistry based molecular subtypes on chemosensitivity and survival patients with breast cancer following NAC. J Breast Cancer 15(2):203–210

    Article  PubMed Central  PubMed  Google Scholar 

  9. Alba E, Chacon JI, Lluch A et al (2012) A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136:487–493

    Article  CAS  PubMed  Google Scholar 

  10. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki67 in early breast cancer. J Clin Oncol 23:7212–7220

    Article  CAS  PubMed  Google Scholar 

  11. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM et al (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Matsubara N, Mukai H, Fujii S et al (2013) Different prognostic significance of Ki67 change between pre- and post-NAC in various subtypes of breast cancer. Breast Cancer Res Treat 137:203–212

    Article  CAS  PubMed  Google Scholar 

  13. Stewart DJ, Chiritescu G, Dahrouge S et al (2007) Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33(2):107–137

    Article  Google Scholar 

  14. Stewart DJ, Raaphorst GP, Yau J et al (1996) Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14(2):115–130

    Article  CAS  PubMed  Google Scholar 

  15. Morrow T, Siegel M, Boone S, Lawless G, Carter W (2002) Chemotherapy dose intensity determination as a quality of care measurement for managed care organisations in the treatment of early-stage breast cancer. Am J Med Qual 17:218–224

    Article  PubMed  Google Scholar 

  16. Moon HG, Im SA, Han W et al (2012) Estrogen receptor status confers a distinct pattern of response to NAC: implications for optimal durations of therapy: distinct patterns of response according to ER expression. Breast Cancer Res Treat 134(3):1133–1140

    Article  CAS  PubMed  Google Scholar 

  17. Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272

    Article  CAS  PubMed  Google Scholar 

  19. McGhan LJ, McCullough AE, Protheroe CA et al (2014) Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 21(2):361–367

    Article  PubMed  Google Scholar 

  20. Teschendorff* AE, Miremadi† A, Pinder† SE et al (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8(8):R157

    Article  PubMed Central  PubMed  Google Scholar 

  21. Chang C-L, Hsu Y-T, Wu C-C et al (2013) Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 73(1):119–127

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Emens LA, Jaffee EM (2005) Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059–8064

    Article  CAS  PubMed  Google Scholar 

  23. Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61

    Article  CAS  PubMed  Google Scholar 

  24. Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059

    Article  CAS  PubMed  Google Scholar 

  25. Falcone T, Bedaiwy MA (2005) Fertility preservation and pregnancy outcome after malignancy. Curr Opin Obstet Gynecol 17(1):21–26

    Article  PubMed  Google Scholar 

  26. Sun ZY, Shen K, Lang JH et al (2003) Effect of chemotherapy to ovary function in ovarian malignancy patients undergoing conservative surgery. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 25(4):431–433

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors declare that they have no financial relationship with the organization that sponsored the study.

Conflict of interest

The authors declare that they have no financial and personal relationships with other people or organizations that can inappropriately influence our work. There is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Xiangya Hospital, Xiangya Road No.87, Kaifu District, Changsha, 410008, Hunan Province, China

    Jia-qi Yuan, Shou-man Wang, Li–li Tang, Jie Mao, Yu-hui Wu, Jian Hai, Sha-yang Luo, Hui-ying Ou, Lei Guo, Li-qiu Liao, Jun Huang, Yan Li, Zhi Xiao, Ke-jing Zhang, Na Luo & Fei-yu Chen

Authors
  1. Jia-qi Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shou-man Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li–li Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-hui Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian Hai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sha-yang Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hui-ying Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Li-qiu Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Zhi Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ke-jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Na Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Fei-yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia-qi Yuan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, Jq., Wang, Sm., Tang, L. et al. Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 151, 405–413 (2015). https://doi.org/10.1007/s10549-015-3418-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3418-z

Keywords

Search

Navigation